Skip to main content
Smart Investors Daily
PY

NASDAQ · PYXS

Pyxis Oncology, Inc. Common Stock

Healthcare · Biotechnology

$1.58

Down-$0.17 (-10.76%)

Updated Nov 17, 2026, 12:52 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
274.21M
P/E ratio
-2.84
Dividend yield
0.00%
52-week range
$1.03 – $5.55
Volume
359.91K
Avg. volume
793.75K

Price performance · PYXS

PYXS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

PYXS closed at $1.58 after 20 trading sessions, down 10.23% for the selected period.

Last close
$1.58
Period change
-10.23%
Period low
$1.58
Period high
$1.98
Daily close
View OHLC price history
PYXS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$1.57$1.60$1.51$1.58359.91K
Nov 12, 2026$1.62$1.625$1.52$1.581M
Nov 11, 2026$1.63$1.68$1.59$1.64665.4K
Nov 10, 2026$1.66$1.735$1.59$1.63592.67K
Nov 9, 2026$1.70$1.795$1.67$1.70881.91K
Nov 6, 2026$1.62$1.74$1.62$1.66560.5K
Nov 5, 2026$1.64$1.675$1.50$1.611.15M
Nov 4, 2026$1.67$1.71$1.565$1.66923.32K
Nov 3, 2026$1.72$1.76$1.62$1.64645.8K
Nov 2, 2026$1.825$1.86$1.625$1.69897.38K
Oct 30, 2026$1.88$1.8848$1.78$1.81686.53K
Oct 29, 2026$1.98$1.9919$1.88$1.89697.23K
Oct 28, 2026$1.83$1.99$1.80$1.98728.12K
Oct 27, 2026$1.70$1.85$1.68$1.841.18M
Oct 26, 2026$1.66$1.72$1.6341$1.69645.78K
Oct 23, 2026$1.70$1.71$1.63$1.68626.78K
Oct 22, 2026$1.74$1.79$1.695$1.71557.51K
Oct 21, 2026$1.85$1.87$1.75$1.76501.33K
Oct 20, 2026$1.76$1.90$1.73$1.841.11M
Oct 19, 2026$1.69$1.79$1.675$1.761.02M

Latest PYXS news

The latest Smart Investors Daily articles mentioning PYXS.

PYXS research

Overview

Company profile and research snapshot.

Company profile

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.50
Implied upside
—
Analysts
15
PYXS recent ratings
DateFirmRatingTarget
Nov 6, 2026WedbushOutperform—
Nov 6, 2026RBC CapitalOutperform—
Sep 10, 2026HC Wainwright & Co.Buy—
Sep 10, 2026WedbushOutperform—
Sep 9, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Nov 3, 2025

Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.